Till Sebastian Clauditz1, Thorsten Rieckmann2,3, Mara Borgmann4,5, Agnes Oetting4,6, Felix Meyer6, Nikolaus Möckelmann4,7, Conrad Droste8, Clara Marie von Bargen1, Christina Möller-Koop1, Melanie Witt1, Kerstin Borgmann6, Kai Rothkamm6, Christian Betz4, Adrian Münscher4,7. 1. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. t.rieckmann@uke.de. 3. Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. t.rieckmann@uke.de. 4. Department of Otorhinolaryngology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 5. Department of Otorhinolaryngology, Asklepios Klinik Nord, Hamburg, Germany. 6. Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7. Department of Otorhinolaryngology, Marienkrankenhaus Hamburg, Hamburg, Germany. 8. University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
PURPOSE: Immune checkpoint inhibition is a therapeutic option in many cancer entities. In head and neck squamous cell carcinoma (HNSCC) targeting of the PD-1/PD-L1 (B7-H1) axis is approved in recurrent/metastatic disease and is being explored in the curative setting. Here, we evaluated two related members of the B7 family, B7-H3 & B7-H4, for their prognostic impact under standard treatment. METHODS: A tissue microarray (TMA) of a single center HNSCC cohort was stained for B7-H3 and B7-H4. Staining intensity and the number of tumor cells stained were assessed, and the expression was scored according to an established algorithm. Staining scores were correlated with clinicopathological parameters and associated with patient survival. mRNA levels of both proteins were associated with patient outcome using the TCGA dataset. RESULTS: mRNA levels of B7-H3 and B7-H4 were not significantly associated with patient survival. TMA analysis revealed interpretable protein staining in 408 samples. Strong staining was the most frequent category for B7-H3 and no staining for B7-H4. In patients with p16-negative oropharyngeal SCC (OPSCC) and in a pooled cohort consisting of p16-negative OPSCC, laryngeal, hypopharyngeal and oral cavity SCC, strong B7-H3 expression was associated with better overall survival. For the latter cohort, this was in part due to reduced lymph node involvement. B7-H3 expression in p16-positive OPSCC and B7-H4 expression were not associated with outcome. CONCLUSION: Despite a possible role in tumor immune escape, B7-H3 was associated with favorable prognosis in HPV-negative HNSCC in our cohort. The underlying mechanisms and a potential impact for B7-H3 targeting remain to be elucidated.
PURPOSE: Immune checkpoint inhibition is a therapeutic option in many cancer entities. In head and neck squamous cell carcinoma (HNSCC) targeting of the PD-1/PD-L1 (B7-H1) axis is approved in recurrent/metastatic disease and is being explored in the curative setting. Here, we evaluated two related members of the B7 family, B7-H3 & B7-H4, for their prognostic impact under standard treatment. METHODS: A tissue microarray (TMA) of a single center HNSCC cohort was stained for B7-H3 and B7-H4. Staining intensity and the number of tumor cells stained were assessed, and the expression was scored according to an established algorithm. Staining scores were correlated with clinicopathological parameters and associated with patient survival. mRNA levels of both proteins were associated with patient outcome using the TCGA dataset. RESULTS: mRNA levels of B7-H3 and B7-H4 were not significantly associated with patient survival. TMA analysis revealed interpretable protein staining in 408 samples. Strong staining was the most frequent category for B7-H3 and no staining for B7-H4. In patients with p16-negative oropharyngeal SCC (OPSCC) and in a pooled cohort consisting of p16-negative OPSCC, laryngeal, hypopharyngeal and oral cavity SCC, strong B7-H3 expression was associated with better overall survival. For the latter cohort, this was in part due to reduced lymph node involvement. B7-H3 expression in p16-positive OPSCC and B7-H4 expression were not associated with outcome. CONCLUSION: Despite a possible role in tumor immune escape, B7-H3 was associated with favorable prognosis in HPV-negative HNSCC in our cohort. The underlying mechanisms and a potential impact for B7-H3 targeting remain to be elucidated.
Authors: A I Chapoval; J Ni; J S Lau; R A Wilcox; D B Flies; D Liu; H Dong; G L Sica; G Zhu; K Tamada; L Chen Journal: Nat Immunol Date: 2001-03 Impact factor: 25.606
Authors: L Bubendorf; J Kononen; P Koivisto; P Schraml; H Moch; T C Gasser; N Willi; M J Mihatsch; G Sauter; O P Kallioniemi Journal: Cancer Res Date: 1999-02-15 Impact factor: 12.701
Authors: Ramaswamy Govindan; Charu Aggarwal; Scott J Antonia; Marianne Davies; Steven M Dubinett; Andrea Ferris; Patrick M Forde; Edward B Garon; Sarah B Goldberg; Raffit Hassan; Matthew D Hellmann; Fred R Hirsch; Melissa L Johnson; Shakun Malik; Daniel Morgensztern; Joel W Neal; Jyoti D Patel; David L Rimm; Sarah Sagorsky; Lawrence H Schwartz; Boris Sepesi; Roy S Herbst Journal: J Immunother Cancer Date: 2022-05 Impact factor: 12.469
Authors: Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz Journal: Cancer Discov Date: 2012-05 Impact factor: 39.397
Authors: Barbara Burtness; Kevin J Harrington; Richard Greil; Denis Soulières; Makoto Tahara; Gilberto de Castro; Amanda Psyrri; Neus Basté; Prakash Neupane; Åse Bratland; Thorsten Fuereder; Brett G M Hughes; Ricard Mesía; Nuttapong Ngamphaiboon; Tamara Rordorf; Wan Zamaniah Wan Ishak; Ruey-Long Hong; René González Mendoza; Ananya Roy; Yayan Zhang; Burak Gumuscu; Jonathan D Cheng; Fan Jin; Danny Rischin Journal: Lancet Date: 2019-11-01 Impact factor: 79.321
Authors: Xavier Castellsagué; Laia Alemany; Miquel Quer; Gordana Halec; Beatriz Quirós; Sara Tous; Omar Clavero; Llúcia Alòs; Thorsten Biegner; Tomasz Szafarowski; Maria Alejo; Dana Holzinger; Enrique Cadena; Edith Claros; Gillian Hall; Jan Laco; Mario Poljak; Maria Benevolo; Elena Kasamatsu; Hisham Mehanna; Cathy Ndiaye; Núria Guimerà; Belen Lloveras; Xavier León; Juan C Ruiz-Cabezas; Isabel Alvarado-Cabrero; Chang-Suk Kang; Jin-Kyoung Oh; Marcial Garcia-Rojo; Ermina Iljazovic; Oluseyi F Ajayi; Flora Duarte; Ashrafun Nessa; Leopoldo Tinoco; Marco A Duran-Padilla; Edyta C Pirog; Halina Viarheichyk; Hesler Morales; Valérie Costes; Ana Félix; Maria Julieta V Germar; Marisa Mena; Arzu Ruacan; Asha Jain; Ravi Mehrotra; Marc T Goodman; Luis Estuardo Lombardi; Annabelle Ferrera; Sani Malami; Estela I Albanesi; Pablo Dabed; Carla Molina; Rubén López-Revilla; Václav Mandys; Manuel E González; Julio Velasco; Ignacio G Bravo; Wim Quint; Michael Pawlita; Nubia Muñoz; Silvia de Sanjosé; F Xavier Bosch Journal: J Natl Cancer Inst Date: 2016-01-28 Impact factor: 13.506